Adamas Announces Final Results from the Two-Year Phase 3 Open-Label Study of GOCOVRI Pharmaceutical Investing
Flexion Therapeutics Announces Publication of Results from Pivotal Phase 3 Study of ZILRETTA Biotech Investing
Opiant Pharmaceuticals Awarded Grant of Approximately $7.4 Million from the National Institutes of Health for Development of OPNT003 Pharmaceutical Investing
Solid Biosciences Provides Update On SGT-001 Clinical Development Program For Duchenne Muscular Dystrophy Biotech Investing
